Cebranopadol Shows Promising Results in Treating Acute Pain
Tris Pharma, Inc. has announced highly encouraging results from its ALLEVIATE-1 phase 3 clinical trial evaluating cebranopadol as a treatment for moderate-to-severe acute pain following abdominoplasty surgery.
The trial achieved its primary endpoint, demonstrating a significant reduction in pain intensity compared to placebo. This breakthrough underscores cebranopadol’s potential to become a groundbreaking solution in the field of acute pain management.
The results showed a strong mean hourly difference of 1.34 on the Numerical Rating Scale (NRS) between cebranopadol and placebo, reflecting substantial pain relief. Importantly, cebranopadol’s safety and tolerability profile were comparable to placebo, reinforcing its suitability as a highly effective and safe option for acute pain patients.
The primary investigator for the ALLEVIATE-1 study, highlighted the magnitude of analgesia observed in the trial, stating that cebranopadol could potentially match the efficacy of opioids without the associated risks.
These findings emphasise the important role cebranopadol could play in safely alleviating acute pain, they noted, adding that the results signal a promising shift in acute pain management.
Tris Pharma’s CEO expressed enthusiasm over the trial’s success, emphasising the urgent need for alternatives to opioids in pain management. They expressed that Cebranopadol has the potential to transform the treatment landscape for acute pain patients by delivering highly effective pain relief without the addiction risk and side effects of opioids.
Looking ahead, Tris Pharma is poised to present the full results of ALLEVIATE-1 at an upcoming medical congress.
In addition, the company is set to unveil data from two other clinical studies in the first quarter of 2025, with plans to submit a New Drug Application (NDA) later this year. Beyond this, Tris Pharma aims to expand cebranopadol’s applications by initiating studies in multiple chronic pain indications in the second half of 2025.
To add some final thoughts, these findings mark an important milestone for cebranopadol, offering new hope to patients and clinicians seeking safer, more effective pain management options. With its strong safety profile and promising efficacy, cebranopadol is poised to reshape the future of acute and chronic pain treatment.
As Tris Pharma continues its research and development efforts, the medical community eagerly anticipates further breakthroughs in this critical area.
News Credits: Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol
Things you may also like:
- Cambridge Cognition Expands Partnership with Actinogen Medical
- Oxford Drug Design Achieves Milestone in AI-Driven Cancer Treatment Development
- New Hope for Prostate Cancer Patients Resistant to Hormone Therapy